EGFR Resisters Patient Portal

Stay informed and get involved in EGFR programs, patient groups, and clinical trials.

Webinar Series

This 3-part webinar series will help you gain a better understanding of the science and language involved in EGFR NSCLC testing and strategies to help lead to better outcomes.


Joshua Bauml, MD and Melina Marmarelis, MD, MSCE

Webinar 1
Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies
  • Review necessary biomarker testing that should be conducted upon disease progression.
  • Consider the pros/cons of liquid biopsy.
  • Discuss common mechanisms of EGFR‐dependent resistance (e.g., C797S) that occur on 1st and 2nd generation EGFR TKI therapies, including osimertinib.
  • Explore treatments and clinical trials that may offer benefit for progression from common EGFR‐ dependent post‐osimertinib mutations.
  • Weigh treatment considerations if CNS disease is still under control on osimertinib.


Zofia Piotrowska, MD and Catherine Meador, MD, PhD

Webinar 2
I Have Another Oncogene Driver! What Are the Implications of This?
  • Outline other oncogene driver mutations that may be found upon progression (e.g., MET amplification, RET fusion, BRAF, HER2, etc.).
  • Explore treatments and clinical trials that may offer benefit for progression associated with secondary, non‐EGFR driver mutations.


Helena A. Yu, MD and Joseph Chan, MD, PhD

Webinar 3
What is Histological Transformation, and Can it Be Treated?
  • Discuss histological transformations that may occur after treatment with EGFR TKIs, including small cell and squamous cell.
  • Explore treatments and clinical trials that may offer benefit for progression associated with histological transformation.

Meet the Moderators

Ivy Elkins
Diagnosed 2014

My name is Ivy Elkins and I was diagnosed at age 47 with EGFR-positive stage IV lung cancer that had metastasized to my bones and brain. I have been treated successfully with targeted therapy medications since my diagnosis, thus allowing me to lead an active life and handle my lung cancer as a chronic disease. I receive my treatment at the University of Chicago and live in the Chicago suburbs with my husband Ben and my two teenaged boys. I have an undergraduate degree in English from Princeton University and a Master’s in Business Administration from the Wharton School at the University of Pennsylvania.

Jill Feldman
Diagnosed 2014

My journey with lung cancer started long before I became a patient. When I was 13 years old, I lost two grandparents and my dad to lung cancer within a period of eight months. Fourteen years later, my mom and close aunt succumbed to the disease within a two-year period. I needed to find a way to redirect my anger into action so I became a volunteer and advocate for lung cancer. Then, as president of LUNGevity Foundation the unthinkable happened. In 2009, at 39 years old with four small children, I was diagnosed with lung cancer.

Additional Resources

Our Supporters

Need More Info?

If you are a patient looking for more information, please send us a note and our expert team will be in touch! 859-260-1717
PO Box 55230
Lexington, Ky 40555

Send a Message

"*" indicates required fields